Merck & Co., Inc.

The award-winning Adept platform, now delivered as a fully managed SaaS solution — with AI capabilities built in

QUAKERTOWN, Pa., May 20, 2026 /PRNewswire/ -- Synergis Software announced the general availability of Adept Cloud, a cloud-native SaaS engineering document management platform built for organizations in manufacturing, utilities, oil and gas, chemicals, pharmaceuticals, and mining — where the accuracy of engineering documentation is a matter of operational safety, regulatory compliance, and project outcomes. Adept Cloud delivers the full capabilities of the award-winning Adept platform in a browser-based environment that is hosted, maintained, and continuously updated by Synergis — no local infrastructure, no VPN, and no IT overhead required.

"We built Adept Cloud because our customers told us where they needed to go — and we made a commitment to get them there. What we built isn't just a cloud version of Adept. It's a modern, cloud-native platform — architected for the security, reliability, and scalability that asset-intensive organizations require for the decade ahead. Adept Cloud is also where we'll continue to innovate — AI is built in, with more to come. And as this platform evolves, it will serve as the foundation for on-premise deployments as well, ensuring every Adept customer has access to the same capabilities, regardless of how they choose to deploy. That's what reaching this moment means to us — it's a milestone for Synergis, and our customers get a platform they can grow with for years to come."

— Kristen Tomasic, President, Synergis Software

Learn more about Adept Cloud.

Built for the Organizations That Can't Afford to Get It Wrong

In asset-intensive industries, the wrong document revision isn't just an inconvenience — it is a safety risk, a compliance failure, an expensive change order, and a project delay. Adept Cloud is built for environments where precision matters — delivering fast access to the right documents, CAD integration, intellectual property protection, and traceability across every decision.

"The question we heard most from engineering organizations was whether a cloud EDMS could really handle the complexity of what they do. The CAD relationships, the controlled workflows, the audit requirements, the scale. Adept Cloud was built to answer that question with confidence. The answer is yes."

— Todd Cummings, Vice President of Product Strategy, Synergis Software

Unlimited Users. No Per-Seat Costs.

Every Adept Cloud plan — Essentials, Professional, and Enterprise — includes unlimited users. No per-seat costs, and no limits on who can access the system, from engineers at their desks to teams in the field or on the plant floor.

Synergis will host an Adept Cloud webinar for customers on June 4, and an Adept Cloud introduction webinar open to all interested organizations on June 17.

Adept AI: Intelligence Where Your Engineering Data Lives

Adept AI is built for the Adept Cloud platform — artificial intelligence capabilities that help engineering organizations surface information faster, accelerate document-intensive work, and extract more value from the engineering data already in their system.

"Engineering information is one of the most valuable and underutilized assets in any industrial organization — critical context buried within tens or hundreds of thousands of documents, largely inaccessible. Adept AI changes that by putting intelligence to work at the platform layer — inside the system where the data already lives, with the governance and security that asset-intensive industries require."

— Scott Lamond, Vice President of Marketing, Synergis Software

Getting Started with Adept Cloud

Adept Cloud is available today. New customers work with their dedicated customer success manager through an onboarding plan that aligns with their Adept Cloud Plan and streamlines time to value. Existing Adept customers can transition to Adept Cloud through a personalized plan designed to minimize disruption and maximize continuity.

Recognition and Customer Trust

Synergis Adept was named to G2's 2026 Best Software Awards as the top-ranked engineering document management platform. The platform holds G2 distinctions for Best Support, Best Relationship, and Highest User Adoption. 95% of verified G2 reviews are rated four or five stars.

About Synergis Software

Synergis Software is the creator of Adept, a leading engineering document management platform trusted by global organizations including Dow, Con Edison, Merck, and General Mills — and named to G2's 2026 Best Software Awards as the top-ranked engineering document management platform. For more than 35 years, Synergis has helped asset-intensive industries — including manufacturing, chemicals, utilities, oil and gas, life sciences, and mining — centralize, govern, and leverage engineering information to accelerate projects, strengthen compliance, and reduce operational risk. Adept is available both as a fully managed SaaS platform and as an on-premise solution.

For more information, visit SynergisSoftware.com.

MEDIA CONTACT

Scott Lamond

Vice President of Marketing, Synergis Software

scott.lamond@synergis.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/synergis-software-launches-adept-cloud-a-cloud-native-engineering-document-management-platform-built-for-asset-intensive-industries-302777751.html

SOURCE Synergis Software

KIRKLAND, QC, April 15, 2026 /CNW/ -- Merck (NYSE: MRK), known as MSD outside the United States and Canada, has released new data examining Canadians' knowledge of human papillomavirus (HPV) across age, gender, and regional groups. The survey revealed notable gaps in awareness--particularly among men and younger adults--even as rates of certain HPV‑related cancers continue to rise across the country.

Key Survey Findings:

• Among younger adult respondents aged 18-24, fewer than half (49%) recognized HPV as a sexually transmitted infection, and about one‑third (34%) of the same group reported not knowing what HPV is.
  
  
  
  
• Nearly one-third of men (31%) reported not knowing what HPV is, and close to half of all men (45%) were not aware of any potential consequences of a persistent HPV infection.
  
   
• Awareness that the rate of certain HPV-related head and neck cancers, such as throat cancer, are increasing among men, was limited across age groups, with 53% of all respondents (both men and women) unaware of this trend.
  
  
  
  
• Men were less likely than women to believe they played a role in helping reduce their risk of contracting or spreading an HPV infection (57% vs. 74%).

For more insights, refer to the HPV Awareness Factsheet.

Understanding the Growing Burden of Certain HPV-Related Cancers

While HPV is most often associated with cervical cancer, throat (oropharyngeal) cancer is now the most common HPV-related cancer in Canada, affecting more men than women. Despite this shift, men appeared more likely to believe that HPV is not a concern to them (16% vs 12%) and were more likely to report not knowing which types of cancers and diseases the infection can cause compared to the overall surveyed population (45% vs. 37%). These knowledge gaps may contribute to lower engagement and reduced health‑seeking behaviours.

The survey also explored how Canadians approached conversations about HPV and the barriers that may hold them back. Nearly three‑quarters (71%) of adult respondents identified at least one obstacle to speaking with a healthcare professional, including lack of awareness or information and feelings of embarrassment. These factors may make it more difficult to ask questions or clarify misconceptions.

"The survey's findings reinforce the importance of HPV disease awareness," said Matthew Thornhill, Executive Director, Vaccines Business Unit at Merck Canada. "We're seeing trends showing that men are less informed about HPV than their female counterparts, along with other findings suggesting they may feel less concerned or inclined to seek information about HPV. Strengthening awareness, particularly among low-awareness groups, is an important step toward encouraging more informed action against HPV."

Overall, the findings highlight opportunities to strengthen public health education in Canada. Clear, accessible information could help Canadians break the stigma around HPV and close persistent knowledge gaps.

While Head & Neck Cancer Awareness Month offers an important opportunity to elevate these conversations, HPV-related risks extend far beyond a single cancer type, or a single month. Sustained, year-round education is essential to ensure Canadians understand the broader health implications of HPV and feel empowered to have informed discussions with a healthcare provider.

To learn more, visit knowhpv.ca and speak to a healthcare provider.

About the Survey

This online survey was conducted by Ipsos on behalf of Merck Canada to assess awareness, perceptions, and understanding of human papillomavirus (HPV) among Canadian adults. The survey was fielded March 6 to March 11, 2026. A total of n=1000 Canadians aged 18 to 47 participated in the survey which was conducted via the Ipsos' panel. Quotas and weighting were used to ensure the sample's composition reflects that of the Canadian population according to census parameters. This survey has a credibility interval of +/- 3.8 per cent 19 times out of 20, of what the results would have been had all Canadians aged 18+ been surveyed. The credibility interval will be wider among subsets of the population.

About Human Papillomavirus (HPV)

Human papillomavirus (HPV) is a common sexually transmitted infection that can spread through intimate skin‑to‑skin contact in the genital area or during vaginal, anal, or oral sex. About 75% of sexually active people will contract at least one HPV infection in their lifetime, often without symptoms. While most infections clear on their own, persistent infection with high‑risk strains could lead to certain types of cancer. HPV is responsible for approximately 100% of cervical cancers, 90% of anal cancers, 60% to 73% of throat (oropharyngeal) cancers, 40% of vaginal and vulvar cancers, and 40% to 50% of penile cancers.

About Merck

At Merck, known as MSD, outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable, and healthy future for all people and communities. For more information about our operations in Canada, visit www.merck.ca and connect with us on LinkedIn @MerckCanada.

Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA

This news release of Merck & Co., Inc., Rahway, N.J., USA (the "company") includes "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company's Annual Report on Form 10-K for the year ended December 31, 2025 and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (www.sec.gov).

© 2026 Merck & Co., Inc., Rahway, NJ, USA, and its affiliates. All rights reserved.

Media Requests:

Merck Canada Media Centre

1-833-906-3725

mediacanada@merck.com

SOURCE Merck